Asarina Pharma - Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11.
ENPNewswire-June 12, 2019--Asarina Pharma - Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11
(C)2019 ENPublishing - http://www.enpublishing.co.uk
Release date- 11062019 - Premenstrual dysphoric disorder (PMDD) has been given its own classification code and for the first time classified clearly as a gynaecological, not mental, disease in the WHO's new International Classification of Diseases, ICD-11.
'This is a crucial step forward for future diagnosis, treatment and reimbursement of our lead indication' says CEO Peter Nordkild.
'The symptoms are severe enough to cause significant distress or impairment and do not represent the exacerbation of a mental disorder'. So reads the new WHO ICD-11 definition of disease 'GA34.41', or PMDD. ICD-11 will, over the coming years, be the new international standard for classifying and reporting diseases, profoundly impacting how diseases are diagnosed, treated and reimbursed worldwide. PMDD, which affects 1-in-20 women of a fertile age worldwide, is Asarina Pharma's lead indication. The company's treatment, Sepranolone, is the first to specifically target PMDD, and is currently in a Phase IIb trial.
NEW CLASSIFICATION WILL DRIVE NEW DIAGNOSES
The inclusion of PMDD in ICD-11 is an important confirmation of growing medical awareness of PMDD worldwide, and a growing scientific consensus that PMDD is a hormonal not psychiatric condition. PMDD is mentioned in the WHO's present ICD-10, but indirectly as a sub-classification under 'Premenstrual tension syndrome'. In ICD-11 PMDD is included as a clearly-named gynaecological disease with its own gynaecological classification code.
DISEASE NOT SYNDROME, HORMONAL NOT PSYCHIATRIC
CEO Peter Nordkild: 'For us the new classification is a fantastic vindication of our 40-years' plus research journey, confirming PMDD is not a mental health condition to be treated by a psychiatrist-but a neuro-hormonal disorder that falls squarely into the gynaecological remit, and which has proved to be treatable using our natural, endogenous compound Sepranolone.'
ICD-11, the eleventh revision of the WHO's International Classification of Diseases, has been several years in development. It was formally adopted May 25 2019. From both the regulatory and...
To continue reading
Request your trial